Monday August 27, 7:01 am Eastern Time
Press Release
SOURCE: InterMune, Inc.
InterMune Announces Key Executive Appointments to Fuel Global Pipeline Development
Company Strengthens Clinical Expertise in Oncology, Pulmonology and Infectious Disease
BRISBANE, Calif., Aug. 27 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN - news) today announced the appointment of several new senior executives to its clinical development team. These new appointments include: Steven Porter, M.D., Ph.D. to the position of Vice President of Clinical Research; Mack Mabry, M.D. to the position of Senior Director of Clinical Research-Oncology; Michael Crager, Ph.D. to the position of Senior Director, Biostatistics; and Williamson Bradford, M.D., Ph.D. to the position of Director of Clinical Research-Pulmonary. InterMune also announced the promotion of Henry Hsu, M.D. to the position of Vice President of Clinical Research.
``Steven, Mack, Mike and Bill bring many years of impressive medical and clinical experience to the Company that will significantly strengthen our clinical development capabilities,'' said James Pennington, M.D., Executive Vice President of Medical and Scientific Affairs for InterMune. ``Each will play a vital role as we continue to expand our clinical development programs from our fourteen existing programs to twenty programs over the next two years.''
``With these key additions, InterMune now has one of the top clinical teams in the biotech industry,'' said W. Scott Harkonen, M.D., President and CEO of InterMune. ``We now have the expertise to aggressively move forward with our oncology, pulmonology and infectious disease programs.''
Dr. Porter brings to InterMune more than five years of biopharmaceutical industry experience. He is board certified in infectious disease as well as in internal medicine and completed his residency in internal medicine at the University of California, San Francisco. Dr. Porter was an Infectious Disease Fellow (Clinical) at the University of California, San Francisco. He was also an Infectious Disease Fellow (Research) and an associate at the Howard Hughes Medical Institute at Stanford University Medical Center. Dr. Porter holds an M.D. from the Vanderbilt University School of Medicine and a Ph.D. (Biochemistry) from Vanderbilt University.
Dr. Hsu brings to the Company more than five years of biopharmaceutical industry experience. He joined InterMune in February 2000 as Senior Director, Clinical Research. Dr. Hsu is board certified in internal medicine as well as in gastroenterology and completed his residency in internal medicine at the University of California, Davis, Medical Center. He was a Fellow (Clinical and Research) in Gastroenterology and a Fellow (Research) at the Howard Hughes Medical Institute at Stanford University Medical Center. Dr. Hsu received his M.D. from the University of California, San Francisco.
Dr. Mabry brings to InterMune four years of experience in the biopharmaceutical industry. He was previously an instructor in Medicine at the Harvard Medical School and an instructor in Oncology at The Johns Hopkins University School of Medicine. Dr. Mabry was a resident in medicine at the Brigham and Women's Hospital as well as at the Brockton Veterans Administration Medical Center. He was a Fellow (Research and Clinical) at The Johns Hopkins Oncology Center. Dr. Mabry holds his M.D. from Duke University School of Medicine.
Dr. Crager brings to the Company twenty years of experience in the biopharmaceutical industry. He has assembled and managed global teams of professionals that were responsible for the biostatistical analysis, data management, pharmacovigilance and informatics for international clinical development programs. Dr. Crager holds a Ph.D. and an M.S. in Statistics from Stanford University.
Dr. Bradford brings to InterMune four years of experience in the biopharmaceutical industry. He is board certified in internal medicine as well as in infectious disease. Dr. Bradford completed his residency in internal medicine at the University of California, San Francisco. He was an Infectious Disease Fellow (Clinical) and a Tuberculosis Fellow (Clinical and Research) at the University of California, San Francisco. Dr. Bradford received his M.D. from the University of North Carolina at Chapel Hill, School of Medicine and a Ph.D. from the University of California, Berkeley, School of Public Health.
InterMune is developing and commercializing innovative products for the treatment of serious pulmonary and infectious diseases and cancer. InterMune markets its lead product, Actimmune®, for the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis. InterMune is currently conducting a Phase III clinical trial with Actimmune® for the treatment of idiopathic pulmonary fibrosis (IPF). InterMune is also conducting or planning clinical trials of Actimmune® for the treatment of multidrug-resistant tuberculosis (MDR TB), atypical mycobacterial infections, ovarian cancer, cryptococcal meningitis, cystic fibrosis, liver fibrosis and non-Hodgkin's lymphoma. InterMune recently acquired rights to Infergen®, which is marketed in the United States and Canada for the treatment of chronic hepatitis C infections. InterMune also markets Amphotec® worldwide for the treatment of invasive aspergillosis. |
